NRC HEALTH (NRC)

NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-26

$22.45+2.37%

Close 2026-10-26 · 1-day change

Investment OutlookAs of Oct 26, 2026

What could strengthen or challenge NRC HEALTH’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	36.6M
EPS	—	0.25
Annual ending 2026-12-31
Revenue	—	118.3M
EPS	—	0.88
Annual ending 2027-12-31
Revenue	—	127M
EPS	—	1.11

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain dividend payments	A supporting condition in NRC HEALTH's published investment case. The stated target is >= $0.16.	Intact	Dividends fall below $0.16 next quarter	Dividend per share: $0.16 per share FY2026-Q2; GAAP. Published target: >= $0.16. Target period is not explicitly aligned with this observation. Source published Aug 4, 20260.16 USD/share · source valueSource reportLast status assessment Oct 26, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4a35a8dd-792c-42b3-b8e4-30b4d95c7784. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 6 of last 6 quarters. Dividend per share was steady at $0.12 from 2025-Q1 through 2026-Q1, then increased to $0.16 in 2026-Q2. The company is maintaining and modestly increasing dividends, delivering on this capital allocation priority. Delivery assessment Oct 26, 2026
Improve operational profitability	Strong leadership can help improve profitability.	Under Pressure	Operating income remains negative next quarter	Operating income: $-3.238M FY2026-Q2; GAAP. Published target: >= $0 million. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026-3,238,000 USD · source valueSource reportLast status assessment Oct 26, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4a35a8dd-792c-42b3-b8e4-30b4d95c7784. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Revenue grew modestly from $33.6M in 2025-Q1 to $35.4M in 2026-Q2. However, operating income declined from $8.6M in 2025-Q1 to a loss of $3.2M in 2026-Q2. The trajectory shows revenue growth but declining profitability, indicating limited progress on operational profitability despite sustained revenue. Delivery assessment Oct 26, 2026
Sustain revenue growth	A primary condition in NRC HEALTH's published investment case. The stated target is >= $36 million.	Under Pressure	Revenue falls below $36 million next quarter	Revenue: $35.392M FY2026-Q2; GAAP. Published target: >= $36 million. Target period is not explicitly aligned with this observation. Source published Aug 4, 202635,392,000 USD · source valueSource reportLast status assessment Oct 26, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4a35a8dd-792c-42b3-b8e4-30b4d95c7784. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Revenue grew modestly from $33.6M in 2025-Q1 to $35.4M in 2026-Q2. However, operating income declined from $8.6M in 2025-Q1 to a loss of $3.2M in 2026-Q2. The trajectory shows revenue growth but declining profitability, indicating limited progress on operational profitability despite sustained revenue. Delivery assessment Oct 26, 2026

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-07	Unavailable	Unavailable	1 / 1
2026-09-08	Unavailable	Unavailable	1 / 1
2026-09-09	Unavailable	Unavailable	1 / 1
2026-09-10	Unavailable	Unavailable	1 / 1
2026-09-11	Unavailable	Unavailable	1 / 1
2026-09-12	Unavailable	Unavailable	1 / 1
2026-09-13	Unavailable	Unavailable	1 / 1
2026-09-14	Unavailable	Unavailable	1 / 1
2026-09-15	Unavailable	Unavailable	1 / 1
2026-09-16	Unavailable	Unavailable	1 / 1
2026-09-17	Unavailable	Unavailable	1 / 1
2026-09-18	Unavailable	Unavailable	1 / 1
2026-09-19	Unavailable	Unavailable	1 / 1
2026-09-20	Unavailable	Unavailable	1 / 1
2026-09-21	Unavailable	Unavailable	1 / 1
2026-09-22	Unavailable	Unavailable	1 / 1
2026-09-23	Unavailable	Unavailable	1 / 1
2026-09-24	Unavailable	Unavailable	1 / 1
2026-09-25	Unavailable	Unavailable	1 / 1
2026-09-26	Unavailable	Unavailable	1 / 1
2026-09-27	Unavailable	Unavailable	1 / 1
2026-09-28	Unavailable	Unavailable	1 / 1
2026-09-29	Unavailable	Unavailable	1 / 1
2026-09-30	Unavailable	Unavailable	1 / 1
2026-10-01	Unavailable	Unavailable	1 / 1
2026-10-02	Unavailable	Unavailable	1 / 1
2026-10-03	Unavailable	Unavailable	1 / 1
2026-10-04	Unavailable	Unavailable	1 / 1
2026-10-05	Unavailable	Unavailable	1 / 1
2026-10-06	Unavailable	Unavailable	1 / 1
2026-10-07	Unavailable	Unavailable	1 / 1
2026-10-08	Unavailable	Unavailable	1 / 1
2026-10-09	Unavailable	Unavailable	1 / 1
2026-10-10	Unavailable	Unavailable	1 / 1
2026-10-11	Unavailable	Unavailable	1 / 1
2026-10-12	Unavailable	Unavailable	1 / 1
2026-10-13	Unavailable	Unavailable	1 / 1
2026-10-14	Unavailable	Unavailable	1 / 1
2026-10-15	Unavailable	Unavailable	1 / 1
2026-10-16	Unavailable	Unavailable	1 / 1
2026-10-17	Unavailable	Unavailable	1 / 1
2026-10-18	Unavailable	Unavailable	1 / 1
2026-10-19	Unavailable	Unavailable	1 / 1
2026-10-20	Unavailable	Unavailable	1 / 1
2026-10-21	Unavailable	Unavailable	1 / 1
2026-10-22	Unavailable	Unavailable	1 / 1
2026-10-23	Unavailable	Unavailable	1 / 1
2026-10-24	Unavailable	Unavailable	1 / 1
2026-10-25	Unavailable	Unavailable	1 / 1
2026-10-26	Unavailable	Unavailable	1 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-06-01	1	0	0
2026-07-01	1	0	0
2026-08-01	1	0	0
2026-09-01	1	0	0
2026-10-01	1	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 27–Oct 26 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 27, 2026–Oct 26, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain dividend paymentsDividend per share: $0.16 per share
Improve operational profitabilityPublished status: Under Pressure
Sustain revenue growthPublished status: Under Pressure

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-46.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

NRC HEALTH outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

NRC is a healthcare business with strong recent financial performance and robust earnings quality, but high risk and expensive valuation make this a premium-priced, execution-sensitive long-term thesis. The thesis is intact, though operating profitability has weakened despite modest revenue growth.

What's priced into NRC HEALTH

NRC trades at a 1.36-times premium to peers, with a durable premium identified as the main valuation driver and an expectations gap of 0.18. Valuation has fallen materially in recent evidence, but the overall tag remains stretched; the snapshot does not give a specific market assumption beyond this premium.

What the fundamentals likely do

Near-term results have been strong, including a recent earnings beat, and the sector backdrop is a tailwind. Over the multi-year view, revenue has grown modestly, but operating income has weakened from a profit to a loss, so progress toward operational profitability remains limited. The CFO departure and CEO transition add execution uncertainty, while the near-term miss risk is described as low despite erratic recent surprises.

What NRC HEALTH hinges on

The key company-level test is whether NRC can keep growing revenue while restoring operating profitability and manage its leadership transitions effectively. The sector backdrop could help if healthcare bellwethers keep beating and raising guidance, but weakening employment or bellwether misses could increase pressure on cyclical healthcare names. Dividend increases have supported the stated capital-allocation priority, but the evidence on the new leadership priority is still limited.